167. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257–1263.
168.Frost AE, the STEP investigators. STEP-open label extension: long-term benefits of inhaled iloprost (ILO) addition to bosentan for treatment of pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2007; 175: Suppl., A1001.
169.Zheng Y, Yang T, Chen G, Hu E, Gu Q, Xiong C. Prostanoid therapy for pulmonary
|
arterial hypertension: a meta-analysis of survival outcomes. Eur J Clin Pharmacol. 2014; |
|||||
|
70(1):13–21. |
|
|
|
|
|
170. |
Davenport A.P., |
Hyndman K.A., Dhaun N., |
Southan C., |
Kohan D.E., Pollock J.S., |
||
|
Pollock D.M., Webb D.J., Maguire J.J. Endothelin. |
Pharmacol Rev. – 2016. – Vol. 68. – |
||||
|
N. 2. – P. 357–418. |
|
|
|
|
|
171. |
Miyagawa K., |
Emoto N. |
Current |
state |
of endothelin receptor antagonism |
|
|
in hypertension and pulmonary |
hypertension // Ther. Adv. |
Cardiovasc. Dis. – 2014. – |
|||
|
Vol. 8. – N. 5. – P. 202–216. |
|
|
|
|
|
172.Aversa M., Porter S., Granton J. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension // Drug Saf. – 2015. – Vol. 38. – N. 5. –
P. 419–435.
173.Galie´ N, Badesch BD, Oudiz R, Simonneau G, McGoon M, Keogh A, Frost A, Zwicke D, Naeije R, Shapiro RS, Olschewski H, Rubin L. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46:529–535.
174.Galie´ N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension randomized, doubleblind, placebocontrolled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117:3010–3019.
175.McGoon M, Frost A, Oudiz R, Badesch BD, Galie` N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135: 122–129.
176.Belinda N. Rivera-Lebron and Michael G. Risbano Ambrisentan: a review of its use in pulmonary arterial hypertension Ther Adv Respir Dis 2017, Vol. 11(6) 233–244.
177.Vachiéry JL, Hoeper MM, Peacock AJ, Sitbon O, Cheli M, Church C, Olsson KM, Palazzini M, Waterhouse B, Langley J, Galié N. Ambrisentan use for pulmonary arterial
131
hypertension in a post-authorization drug registry: The VOLibris Tracking Study. J Heart
Lung Transplant. 2017; 36(4):399–406.
178.Shapiro S, Pollock DM, Gillies H, Henig N, Allard M, Blair C, Anglen C, Kohan DE. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol. 2012; 110(9):1373–1377.
179.Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001; 358:1119–1123.
180.Humbert M, Barst RJ, Robbins IM, Channick RN, Galie` N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24:353–359.
181.Galie` N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H, Meyer GMB, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008; 371:2093–2100.
182.Galie` N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, Chiossi E, Landzberg M. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48–54.
183.Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long term outcome with first line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J. 2006; 27(5): 589–595.
184.Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmcol Ther 2001; 69(4):223–231.
185.McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46: 405–413.
186.Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008; 327(3):736–745.
187.Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369(9): 809-818.
132
188.Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin LJ, Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N. Effect of Macitentan on Hospitalizations Results From the SERAPHIN Trial JACC: Heart Failure 2015; 3(1):1–8.
189.Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, Kim NH, Martin N,
Savale |
L, |
Krowka |
M. |
Macitentan |
for |
the |
treatment |
of |
portopulmonary hypertension (PORTICO): a multicentre, |
randomised, double-blind, |
|||||||
placebo-controlled, phase 4 trial.Lancet Respir Med. 2019; 7(7):594–604. |
|
|
||||||
190.Grünig E, Ohnesorge J, Benjamin N, Burhenne J, Enderle Y, Egenlauf B, Fischer C, Harutyunova S, Huppertz A, Klose H, Haefeli WE. Plasma Drug Concentrations in Patients with PAH on Combination Treatment. Respiration 2017; 94(1):26–37.
191.Chrysant S.G. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with
cardiovascular disease and hypertension // Curr. Hypertens. Rep. – 2013. – Vol. 15. –
N.5. –P. 475–483.
192.Galie` N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G, the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148–2157.
193.Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study.
JAm Coll Cardiol 2004; 43:1149–1153.
194.Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010; 31:1124–1131.
195.Singh T, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebocontrolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151:851.e1–851.e5.
196.Мартынюк Т. В., Чазова И. Е. Роль силденафила в лечении пациентов легочной артериальной гипертензией. Системные гипертензии 2012; №2: с.23–29.
197.Ghofrani H.A., Humbert M., Langleben D., Schermuly R., Stasch J.P., Wilkins M.R., Klinger J.R. Riociguat: Mode of action and clinical development in pulmonary hypertension // Chest. – 2016. – Jun. 2. – pii: S0012–3692(16)49111–49117.
133
198.Ghofrani H.A., Humbert M., Langleben D., Schermuly R., Stasch J.P., Wilkins M.R., Klinger J.R. Riociguat: Mode of action and clinical development in pulmonary hypertension // Chest. – 2016. – Jun. 2. – pii: S0012–3692(16)49111–49117.
199.Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369(4): 330–340.
200.Hossein-Ardeschir Ghofrani et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4: 361–371.
201.Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie` N, Degano B, Bonderman D, Kurzyna M, Efficace M, Giorgino R, Lang IM. Selexipag, an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012; 40:874–880.
202.Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522–2533.
203.Lang I, Gaine S, Galie N, et al. Effect of selexipag on long term outcomes in patients with pulmonary arterial hypertension (PAH) receiving one, two or no PAH therapies at baseline: results from the GRIPHON study [abstract 2365].Eur Heart J. 2015; 36(suppl 1):381–382.
204. Fox B.D., Shtraichman O., Langleben D., Shimony A., Kramer M.R. Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Metaanalysis. Can J Cardiol. 2016 Dec; 32(12):1520–1530.
205.Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a metaanalysis. Lancet Respir Med. 2016; 4(4):291–305.
206.Pan J, Lei L, Zhao C. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis Clin Exp Rheumatol. 2018; 36(6):1095–1102.
207.Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study
Group. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial
134
hypertension‒related hospitalization in the AMBITION trial. J Heart Lung
Transplant 2019; 38(2):194–202.
208.Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study// Am J Cardiovasc Drugs.-2018.-Vol.18.-N1.-P.37–47.
209.Sitbon O, Jaïs X, Savale L, Cottin V et al Upfront triple combination therapy in pulmonary arterial hypertension: a pilot studyю Eur Resp J 2014; 43: 1691–1697.
210.Burks M, Stickel S, Galiè N. Pulmonary Arterial Hypertension: Combination Therapy in Practice. Am J Cardiovasc Drugs. 2018; 18(4): 249–257.
211.Hoeper MM, Simonneau G, Corris PA, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017; 50: 1602425.
212.Politi MT, Caruson NA, Lescano J, et al. Switch from bosentan to macitentan in adult outpatients with pulmonary arterial hypertension: a real-world study J Heart Lung Transplant. 2017; 36(4S):S166.
213.Blok IM, van Riel ACMJ, van Dijk APJ et al. From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement? Int J Cardiol 2017; 227: 51–52.
214.Kurzyna M., Dabrowski M., Bielecki D., Fijalkowska A., Pruszczyk P., Opolski G.,
Burakowski J., Florczyk M., Tomkowski W.Z., Wawrzynska L., |
Szturmowicz M., |
|
Torbicki A. Atrial septostomy in treatment of end-stage right |
heart |
failure in patients |
with pulmonary hypertension // Chest. – 2007 – Vol. 131. – N. 4. |
– P. 977–983. |
|
215.Горбачевский С. В., Пурсанов М. Г., Шмальц А. А., Дадабаев Г. М.,Нишонов Н. А.,
Пардаев Д. Б., Хачатурова И. Ю., Алекян Б. Г. Результаты атриосептостомии со стентированием у больных с идиопатической и схожими формами легочной артериальной гипертензии. Грудная и сердечно-сосудистая хирургия 2019.-N 2.-
С.100–113.
216.Khan MS, Memon MM, Amin E, Yamani N, Khan SU, Figueredo VM, Deo S, Rich JD,
Benza RL, Krasuski RA. Use of Balloon Atrial Septostomy in |
Patients With |
Advanced Pulmonary Arterial Hypertension: A Systematic Review and |
Meta-Analysis. |
Chest. 2019; 156(1):53–63. |
|
135